Kontomanolis EN, Kalagasidou SFZ. MicroRNAs as potential serum biomarkers for early detection of ectopic pregnancy. Cureus 2018; 10: e2344.
Miyake M, Goodison S, Lawton A, et al. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 2015; 34: 890-901.
Bartel DP, Lee R, Feinbaum R. MicroRNAs : genomics, biogenesis, mechanism, and function genomics. Cell 2004; 116: 281-97.
Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-34.
MacFarlane L-A, Murphy P. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537-61.
Longatto FA, Lopes JM, Schmitt FC. Angiogenesis and breast cancer. J Oncol 2010; 2010: 1782-90.
Folkman J, Judah F. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27.
Zou Q, Tang Q, Pan Y, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med 2017; 14: 1009-16.
Zou Q, Yi W, Huang J, et al. MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. Exp Ther Med 2017; 14: 1198-204.
Li W, Li G, Fan Z, et al. Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A. Oncol Lett 2017; 14: 2559-65.
Zehentmayr F, Hauser-Kronberger C, Zellinger B, et al. HSA-miR-375 is a predictor of local control in early stage breast cancer. Clin Epigenetics 2016; 8: 28.
Sheng J, Xu Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim Biophys Sin Sinica 2016; 48: 399-410.
He T, Qi F, Jia L, et al. Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p. Cancer Lett 2015; 368: 115-25.
Rykala J, Przybylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17: 809-17.
Roth C, Rack B, Müller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
Schneble E, Jinga D-C, Peoples G. Breast cancer immunotherapy. Maedica (Buchar) 2015; 10: 185-91.
Page DB, Naidoo J, McArthur HL. Emerging immunotherapy strategies in breast cancer. Immunotherapy 2014; 6: 195-209.
Roth C, Rack B, Muller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013; 139: 223-9.
Smith L, Baxter EW, Chambers PA, et al. Down-regulation of miR-92 in breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS One 2015; 10(10): e0139698.
McArthur HL, Page DB. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. Clin Adv Hematol Oncol 2016; 14: 922-33.
Bachelder RRE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-40.
Yan L-X, Huang X-F, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-60.
Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19: 439-48.
Zhu S, Si ML, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282: 14328-36.
Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
Tsai H-P, Huang S-F, Li C-F, et al. Differential microRNA expression in breast cancer with different onset age. PLoS One 2018; 13: e0191195.
Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol 2013; 9: 53-9.
Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013; 34: 163-9.
Zhang J, Yang J, Zhang X, et al. MicroRNA-10b expression in breast cancer and its clinical association. PLoS One 13(2): e0192509.
Wu Q, Wang C, Lu Z, et al. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012; 413: 1058-65.
Zhou J, Tian Y, Li J, et al. MiR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 433: 207-12.
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
Wang S, Bian C, Yang Z, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461-6.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8.
Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-10.
Edmonds MD, Hurst DR, Vaidya KS, et al. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 2009; 125: 1778-85.
Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4(9): e7181.
Campo L, Turley H, Han C, et al. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J Pathol 2005; 205: 585-91.
Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997; 123: 167-72.
Montero S, Guzmán C, Cortés-Funes H, et al. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res 1998; 4: 2161-8.
He T, Qi F, Jia L, et al. MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol 2014; 232: 499-508.
Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-84.
Kuhnert F, Mancuso MR, Hampton J, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008; 135: 3989-93.
Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-26.
Otsuka M, Zheng M, Hayashi M, et al. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest 2008; 118: 1944-54.
Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic under hypoxia. PLoS One 2006; 1(1): e116.
Wang CD, Long K, Jin L, et al. Identification of conserved microRNAs in peripheral blood from giant panda: Expression of mammary gland-related microRNAs during late pregnancy and early lactation. Genet Mol Res 2015; 14: 14216-28.
Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108: 3068-71.
Kuehbacher A, Urbich C, Zeiher AM, et al. Role of dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101: 59-68.
Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 2012; 10: 42.
Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
Iorio MV, Ferracin M, Liu C, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
Eastlack S, Alahari S. MicroRNA and breast cancer: understanding pathogenesis, improving management. Noncoding RNA 2015; 1: 17-43.
Chakrabarti M, Khandkar M, Banik NL, et al. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 2012; 1454: 1-13.
Tashkandi H, Shah N, Patel Y, et al. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience 2015; 2: 924-9.
Lee JA, Lee HY, Lee ES, et al. Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer 2011; 14: 269-75.
Persson H, Kvist A, Rego N, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71: 78-86.
Wee EJH, Peters K, Nair SS, et al. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-miR-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 2012; 31: 4182-95.
Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11: R27.
Kurozumi S, Yamaguchi Y, Kurosumi M, et al. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 2017; 62: 15-24.
Lyng MB, Lænkholm AV, Søkilde R, et al. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: a DBCG study. PLoS One 2012; 7(5): e36170.
Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 2014; 233: 368-79.
Bacci M, Giannoni E, Fearns A, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res 2016; 76: 1615-26.
Yu X, Li R, Shi W, et al. Silencing of microRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother 2016; 77: 37-44.
Mertens-Talcott SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013; 52: 591-602.
Cheng C, Fu X, Alves P, et al. MRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol 2009; 10(9): R90.
Zhu W, Qin W, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009; 2: 89.
Vazquez-martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced ‘cytokine signature’ in breast cancer. Eur J Cancer 2007; 43: 1117-24.
Mojtahedi Z, Safaei A, Yousefi Z, et al. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011; 15: 409-18.
Papa A, Caruso D, Tomao S, et al. Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opin Ther Targets 2015; 19: 55-75.
Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10: 507-17.
Lü L, Mao X, Shi P, et al. MicroRNAs in the prognosis of triple-negative breast cancer. Medicine (Baltimore) 2017; 96(22): e7085.
Yao L, Liu Y, Cao Z, et al. MicroRNA-493 is a prognostic factor in triple-negative breast cancer. Cancer Sci 2018; 109(7): 2294-301.
YI B. Ma R, Xi Y. Abstract 5180: MicroRNA and triple negative breast cancer. Cancer Res 2018; 78: 5180.
Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther 2012; 13: 1123-40.
Borin TF, Zuccari DAPC. Jardim-Perassi B V, et al HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice. PLoS One 2014; 9(12): e116247.